Literature DB >> 7905364

c-erbB-2 Oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix.

K Oka1, T Nakano, T Arai.   

Abstract

BACKGROUND: A polyclonal antihuman c-erbB-2 oncoprotein antibody recognized c-erbB-2 oncoprotein in routinely formaldehyde-fixed, paraffin-embedded specimens.
METHODS: Specimens taken from 192 patients with Stage III squamous cell carcinoma of the cervix treated with radiation therapy alone were investigated for c-erbB-2 oncoprotein expression using an immunohistochemical method.
RESULTS: Cancer cells that were positive for c-erbB-2 oncoprotein showed a surface membrane staining pattern. Of the 192 patients, 143 were negative for c-erbB-2 oncoprotein, 12 were weakly positive or ambiguous, 31 were positive, and 6 were strongly positive. The 5-year survival rate of the 155 patients who tested c-erbB-2 negative or weakly positive was significantly better than that of the 37 patients whose results were positive or strongly positive (61% versus 41%, P = 0.022).
CONCLUSION: c-erbB-2 Oncoprotein expression in cancer cells may imply a poor prognosis for patients with Stage III squamous cell carcinoma of the cervix treated with radiation therapy alone.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905364     DOI: 10.1002/1097-0142(19940201)73:3<668::aid-cncr2820730327>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix.

Authors:  K Heselmeyer; E Schröck; S du Manoir; H Blegen; K Shah; R Steinbeck; G Auer; T Ried
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

Review 2.  Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer.

Authors:  F J Crowley; R E O'Cearbhaill; D C Collins
Journal:  Cancer Treat Rev       Date:  2021-05-23       Impact factor: 13.608

3.  HER2 expression in cervical cancer as a potential therapeutic target.

Authors:  Alma Chavez-Blanco; Victor Perez-Sanchez; Aurora Gonzalez-Fierro; Teresa Vela-Chavez; Myrna Candelaria; Lucely Cetina; Silvia Vidal; Alfonso Dueñas-Gonzalez
Journal:  BMC Cancer       Date:  2004-09-01       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.